Edition:
United Kingdom

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

0.97USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,861
52-wk High
$3.70
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Oasmia Pharmaceutical Q2 operating loss shrinks
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Oasmia Pharmaceutical Ab ::OASMIA PHARMACEUTICAL AB Q2 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 1,651 COMPARED TO TSEK 56 IN THE SECOND QUARTER THE PREVIOUS YEAR ​.OASMIA PHARMACEUTICAL AB Q2 ‍OPERATING LOSS WAS TSEK 22,129 COMPARED TO TSEK 35,867 IN THE SECOND QUARTER THE PREVIOUS YEAR ​.  Full Article

Oasmia Q4 operating loss widens
Thursday, 8 Jun 2017 

June 8 (Reuters) - Oasmia Pharmaceutical Ab ::Q4 consolidated net sales amounted to 44,000 SEK compared to 59,000 in q4 previous year.Q4 operating loss was 37 mln SEK compared to a loss of 31 mln SEK in q4 previous year.Says the board does not intend to propose any dividends for the financial year May 1, 2016 – April 30, 2017..  Full Article

Oasmia Pharmaceutical Q1 loss per share SEK 0.34
Friday, 2 Sep 2016 

Oasmia Pharmaceutical AB:Q1 loss per share SEK 0.34.  Full Article

Oasmia Pharmaceutical Q1 operating loss narrows
Friday, 2 Sep 2016 

Oasmia Pharmaceutical AB : Q1 consolidated net sales amounted to TSEK 36 compared to TSEK 219 in Q1 previous year .Q1 operating loss was TSEK 32,343 compared to a loss of TSEK 37,819 in Q1 previous year.  Full Article

Oasmia names Fredrik Gynnerstedt as new Chief Financial Officer
Wednesday, 31 Aug 2016 

Oasmia Pharmaceutical AB :Says appoints Fredrik Gynnerstedt as Chief Financial Officer.  Full Article

Oasmia Pharmaceutical Q4 operating loss widens
Friday, 3 Jun 2016 

Oasmia Pharmaceutical AB : Q4 operating loss was TSEK 30,619 compared to a loss of TSEK 28,250 in Q4 previous year .Q4 consolidated net sales amounted to TSEK 59 compared to TSEK 36 in Q4 previous year.  Full Article

Oasmia Pharmaceutical AB announces positive overall survival results from Phase III study of apealea/paclical for treatment of ovarian cancer
Wednesday, 27 Apr 2016 

Oasmia Pharmaceutical AB:Announces positive overall survival results from Phase III study of apealea/paclical for treatment of ovarian cancer.Says Overall Survival data from Phase III study meets endpoint and demonstrates non-inferiority favoring Paclical/Apealea.Says will form basis for application seeking marketing approval in the United States anticipated for the late 2016 or early 2017.  Full Article

Oasmia completes private placements of SEK 45.5 mln
Friday, 15 Apr 2016 

Oasmia Pharmaceutical AB:Says successfully completes private placements of new convertible instruments and new shares in the total amount of 45.5 million Swedish crowns.Says intends to use the proceeds from the Private Placements to strengthen the working capital as well as finance the continued operations and further development of additional human and veterinary products based on the XR-17 technology.  Full Article

Oasmia Pharmaceutical AB reports positive clinical study results for XR17
Tuesday, 5 Apr 2016 

Oasmia Pharmaceutical AB:Says reports positive clinical study results for XR17 nanotechnology.Says recently completed a single center, randomized, single-blind, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of XR17 and XMeNa, one of the components of XR17, after performing single ascending doses in 48 healthy subjects.Says XR17 has been used in several previously conducted clinical trials without any adverse events connected to the substance, a result that has been confirmed and reinforced by this study.Says the confirmation of XR17 as a drug delivery system creates the potential for licensing and deployment opportunities in additional therapeutics outside of the oncology treatment sector.  Full Article

Oasmia Pharmaceutical submits marketing authorization application to EMA for Apealea
Monday, 8 Feb 2016 

Oasmia Pharmaceutical AB:Has submitted a marketing authorization application to the European Medicines Agency for its lead cancer product Apealea.  Full Article

BRIEF-Oasmia receives marketing approval for Paclical in Kazakhstan

* OASMIA PHARMACEUTICAL RECEIVES MARKETING APPROVAL FOR PACLICAL® IN KAZAKHSTAN Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)